News Formycon AG Börse Stuttgart

Equities

FYB

DE000A1EWVY8

Real-time Estimate Tradegate Other stock markets 03:23:38 2024-06-13 am EDT			5-day change	1st Jan Change
48.65 ^EUR	+0.72%		-1.83%	-13.13%

Apr. 25	Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 18	Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda	01:33am	EQ
Updates On Aflibercept Biosimilar Approvals And BPCIA Litigation	Jun. 11	AQ
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders	May. 16	AQ
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region	May. 15	EQ
Formycon reports on successful operating business and financial figures for the first quarter of 2024	May. 08	EQ
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich	May. 07	EQ
Formycon hosts conference call on the results of the first quarter 2024	May. 02	EQ
DD: Formycon AG: Dr. Marc Mikulcik, buy	Apr. 29	EQ
Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance	Apr. 25	EQ
DD: Formycon AG: Dr. Stefan Glombitza, buy	Apr. 24	EQ
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	Apr. 22	AQ
Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024	Apr. 22	EQ
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast	Apr. 12	EQ
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year	Apr. 12	EQ
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)	Apr. 11	EQ
Fresenius Kabi And Formycon Reach Settlement Agreement For Ustekinumab Biosimilar Candidate In Europe And Canada	Apr. 03	AQ
Updates On Aflibercept BPCIA Litigation	Mar. 26	AQ
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Formycon AG Börse Stuttgart

Equities

FYB

DE000A1EWVY8

Summary

Filters